GoodRx Holdings Inc Releases Second Quarter 2024 Financial Results
GoodRx Holdings, Inc. Releases Second Quarter 2024 Financial Results
GoodRx Holdings, Inc. (NASDAQ:GDRX), the leading prescription savings platform in the U.S., reported its financial results for the second quarter of 2024.
Key Financial Metrics
Metric | Q2 2024 | Q2 2023 | YoY Change | Consensus Estimate | Beat/Miss |
---|---|---|---|---|---|
Revenue | $200.6M | $189.7M | +6% | $200.44M | Beat |
EPS | $0.09 | $0.09 | 0% | $0.09 | Inline |
Net Income | $6.7M | $58.8M | -88.6% | Not provided | Not applicable |
Adjusted Net Income | $32.4M | $28.4M | +14.1% | Not provided | Not applicable |
Adjusted EBITDA | $65.4M | $53.5M | +22.2% | Not provided | Not applicable |
Adjusted EBITDA Margin | 32.6% | 28.2% | +4.4pp | Not provided | Not applicable |
Interpretation: GoodRx met its revenue and EPS consensus estimates, demonstrating stable performance. Revenue increased year-over-year by 6%, driven largely by growth in the prescription transactions segment. However, net income saw a significant decline primarily due to the absence of a $46.7 million income tax benefit recognized in the prior year. Adjusted metrics indicate operational improvements and cost efficiencies.
Revenue Performance by Segment
Segment | Q2 2024 | Q2 2023 | YoY Change |
---|---|---|---|
Prescription Transactions | $146.7M | $136.5M | +7% |
Subscription Revenue | $22.0M | $23.9M | -8% |
Pharma Manufacturer Solutions | $26.5M | $24.3M | +9% |
Other Revenue | $5.4M | $4.9M | +10% |
Interpretation: Revenue from the prescription transactions segment grew 7% year-over-year, primarily driven by an 8% increase in Monthly Active Consumers. Subscription revenue decreased by 8% due to the termination of the Kroger Savings Club. Pharma manufacturer solutions revenue increased by 9%, driven by ongoing market penetration and growth in point-of-sale discount programs. Other revenue grew by 10%.
Key Operational Metrics
Operational Metric | Q2 2024 | Q2 2023 | YoY Change |
---|---|---|---|
Number of Consumers | 7 million | Not provided | Not applicable |
CEO Comments: "We're proud of the progress we're making against our key priorities, especially when it comes to strengthening our relationships with retail and PBM partners, scaling our offerings around brand medications, and deepening our relationships with patients," said Scott Wagner, Interim Chief Executive Officer of GoodRx. "While the retail pharmacy space is experiencing a bit of choppiness, we believe GoodRx's value proposition of providing affordable access to medications has never been more important and we are creating ways to enrich that value proposition both for healthcare ecosystem partners and, most importantly, for our consumers."
Dividends or Share Repurchase Program
No information on dividends or share repurchase programs was provided.
Forward Guidance
For the third quarter of 2024, GoodRx is guiding to revenue and adjusted revenue between $193 million and $197 million and Adjusted EBITDA Margin of about 32%. For the full year 2024, the Company expects revenue and adjusted revenue to be at the lower end of the previous guidance range of $800 million to $810 million. The full year guidance includes approximately $5 million of anticipated impact from Rite Aid's store closures. The Company also anticipates over $255 million of Adjusted EBITDA, up about 17% from 2023.
Stock Price Movement
The company's stock price fell by 8.36% following the earnings release, indicating an adverse market reaction possibly driven by the drop in net income and cautious forward guidance.
In summary, GoodRx demonstrated stable revenue growth and operational improvements, despite the decline in net income. The market reaction reflects concerns over the impact of external challenges and future uncertainties.
Impressive Revenue Growth in Third Quarter 2024 51Talk Q3 2024 Earnings Report51Talk Online Educat
Costco Wholesale Corporation Reports First Quarter Financial Results
Quanex Building Products Corporation Reports Q4 and Fiscal 2024 Financial Results
Share